Diagnostic and prognostic value of the detection of antibodies against keratin and cyclic citrullinated peptides in rheumatoid arthritis
Haute Autorite de Sante/French National Authority for Health
Record ID 32007000212
French
Authors' objectives:
To assess the diagnostic and prognostic value of the anti-keratin (AKA) and anti-cyclic citrullinated peptide (ACCP) tests in rheumatoid arthritis in order to advise French National Health Insurance (NHI) on reimbursement.
Authors' results and conclusions:
The sensitivity of the AKA test was 9-61%; its specificity was 92-96% (5 case series). There was no relationship between initial detection of AKA and radiographic damage after 2 and 5 years of follow up (2 case series). The sensitivity of the ACCP test was 41-77%; its specificity was 94-98% (7 case series). The initial detection of ACCP was a predictive factor for radiographic damage at 2 and 5 years of follow up (4 case series). ACCP detection can lead to earlier disease management and/or to more aggressive treatment (expert opinion).
Authors' recommendations:
The ACCP test is indicated for the diagnosis and the prognostic evaluation of rheumatoid arthritis unlike the AKA test. HAS has advised French NHI to reimburse the ACCP test and to cease reimbursement of the AKA test.
Further research/reviews required: -the impact of the initial detection of ACCP on patient treatment and disease progression; -the value of the ACCP test in monitoring disease progression after anti-TNF treatment.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.has-Sante.fr
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
France
MeSH Terms
- Sensitivity and Specificity
- Arthritis, Rheumatoid
- Autoantibodies
- Biomarkers
- Citrulline
- Keratins
- Peptides, Cyclic
- Rheumatoid Factor
Contact
Organisation Name:
Haute Autorité de Santé
Contact Address:
2 avenue du Stade de France, 93218 Saint-Denis La Plaine Cedex, France. Tel: +33 01 55 93 71 88; Fax: +33 01 55 93 74 35;
Contact Name:
has.seap.secretariat@has-sante.fr
Contact Email:
has.seap.secretariat@has-sante.fr
Copyright:
Haute Autorite de Sante/French National Authority for Health (HAS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.